Ocular cicatricial pemphigoid: manifestations and management
Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include...
Gespeichert in:
| Veröffentlicht in: | Current allergy and asthma reports 2005-07, Vol.5 (4), p.333-338 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 338 |
|---|---|
| container_issue | 4 |
| container_start_page | 333 |
| container_title | Current allergy and asthma reports |
| container_volume | 5 |
| creator | Chang, John H McCluskey, Peter J |
| description | Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients. |
| doi_str_mv | 10.1007/s11882-005-0078-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_879471426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408994471</sourcerecordid><originalsourceid>FETCH-LOGICAL-p135t-ad576f75907c35ed96a812a535c5c8d365a285c4fb0c8618253edfe30b2e58c23</originalsourceid><addsrcrecordid>eNo1j0lPwzAQhS0EoqXwA7igiLvBS8YL4oIqNqlSL3COJrZTXGXDSQ78e1JRDk9v9PRpZh4h15zdccb0_cC5MYIyBrO0ofaELDnInCrJ4fQwC0u1FGJBLoZhz5iYMXFOFhys0kzbJXncuqnGlLnocEzRRayzPjT9V9x10T9kDbaxCsOIY-zaIcPWHyLchSa04yU5q7AewtXRV-Tz5flj_UY329f39dOG9lzCSNGDVpUGy7STELxVaLhAkODAGS8VoDDg8qpkzihuBMjgqyBZKQIYJ-SK3P7t7VP3Pc3fFPtuSu18sjDa5prnQs3QzRGayib4ok-xwfRT_HeVvxxqVbE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879471426</pqid></control><display><type>article</type><title>Ocular cicatricial pemphigoid: manifestations and management</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chang, John H ; McCluskey, Peter J</creator><creatorcontrib>Chang, John H ; McCluskey, Peter J</creatorcontrib><description>Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients.</description><identifier>ISSN: 1529-7322</identifier><identifier>EISSN: 1534-6315</identifier><identifier>DOI: 10.1007/s11882-005-0078-9</identifier><identifier>PMID: 15967079</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Cicatrix - etiology ; Cyclophosphamide - therapeutic use ; Eye Diseases - diagnosis ; Eye Diseases - drug therapy ; Eye Diseases - etiology ; Humans ; Immunologic Factors - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Medical treatment ; Methotrexate - therapeutic use ; Pemphigoid, Benign Mucous Membrane - complications</subject><ispartof>Current allergy and asthma reports, 2005-07, Vol.5 (4), p.333-338</ispartof><rights>Current Science Inc 2005.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15967079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, John H</creatorcontrib><creatorcontrib>McCluskey, Peter J</creatorcontrib><title>Ocular cicatricial pemphigoid: manifestations and management</title><title>Current allergy and asthma reports</title><addtitle>Curr Allergy Asthma Rep</addtitle><description>Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients.</description><subject>Cicatrix - etiology</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Eye Diseases - diagnosis</subject><subject>Eye Diseases - drug therapy</subject><subject>Eye Diseases - etiology</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Medical treatment</subject><subject>Methotrexate - therapeutic use</subject><subject>Pemphigoid, Benign Mucous Membrane - complications</subject><issn>1529-7322</issn><issn>1534-6315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo1j0lPwzAQhS0EoqXwA7igiLvBS8YL4oIqNqlSL3COJrZTXGXDSQ78e1JRDk9v9PRpZh4h15zdccb0_cC5MYIyBrO0ofaELDnInCrJ4fQwC0u1FGJBLoZhz5iYMXFOFhys0kzbJXncuqnGlLnocEzRRayzPjT9V9x10T9kDbaxCsOIY-zaIcPWHyLchSa04yU5q7AewtXRV-Tz5flj_UY329f39dOG9lzCSNGDVpUGy7STELxVaLhAkODAGS8VoDDg8qpkzihuBMjgqyBZKQIYJ-SK3P7t7VP3Pc3fFPtuSu18sjDa5prnQs3QzRGayib4ok-xwfRT_HeVvxxqVbE</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Chang, John H</creator><creator>McCluskey, Peter J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200507</creationdate><title>Ocular cicatricial pemphigoid: manifestations and management</title><author>Chang, John H ; McCluskey, Peter J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p135t-ad576f75907c35ed96a812a535c5c8d365a285c4fb0c8618253edfe30b2e58c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Cicatrix - etiology</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Eye Diseases - diagnosis</topic><topic>Eye Diseases - drug therapy</topic><topic>Eye Diseases - etiology</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Medical treatment</topic><topic>Methotrexate - therapeutic use</topic><topic>Pemphigoid, Benign Mucous Membrane - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, John H</creatorcontrib><creatorcontrib>McCluskey, Peter J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Current allergy and asthma reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, John H</au><au>McCluskey, Peter J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular cicatricial pemphigoid: manifestations and management</atitle><jtitle>Current allergy and asthma reports</jtitle><addtitle>Curr Allergy Asthma Rep</addtitle><date>2005-07</date><risdate>2005</risdate><volume>5</volume><issue>4</issue><spage>333</spage><epage>338</epage><pages>333-338</pages><issn>1529-7322</issn><eissn>1534-6315</eissn><abstract>Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>15967079</pmid><doi>10.1007/s11882-005-0078-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1529-7322 |
| ispartof | Current allergy and asthma reports, 2005-07, Vol.5 (4), p.333-338 |
| issn | 1529-7322 1534-6315 |
| language | eng |
| recordid | cdi_proquest_journals_879471426 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Cicatrix - etiology Cyclophosphamide - therapeutic use Eye Diseases - diagnosis Eye Diseases - drug therapy Eye Diseases - etiology Humans Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Medical treatment Methotrexate - therapeutic use Pemphigoid, Benign Mucous Membrane - complications |
| title | Ocular cicatricial pemphigoid: manifestations and management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T22%3A19%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20cicatricial%20pemphigoid:%20manifestations%20and%20management&rft.jtitle=Current%20allergy%20and%20asthma%20reports&rft.au=Chang,%20John%20H&rft.date=2005-07&rft.volume=5&rft.issue=4&rft.spage=333&rft.epage=338&rft.pages=333-338&rft.issn=1529-7322&rft.eissn=1534-6315&rft_id=info:doi/10.1007/s11882-005-0078-9&rft_dat=%3Cproquest_pubme%3E2408994471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879471426&rft_id=info:pmid/15967079&rfr_iscdi=true |